13-Jan-2026 8:00 AM CST - Business Wire Acadia Pharmaceuticals Provides Business and Pipeline Updates at 44th Annual J.P. Morgan Healthcare Conference Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced multiple business updates and progress on the Company's neurological and rare disease drug candidates, which will be discussed today during a presentation by Catherine Owen Adams, Chief Executive Officer, at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, CA. 2026 marks a pivotal year for Acadia as we advance our strategy built for sustained growth and pipeline advancement, said Catherin
18-Dec-2025 3:05 PM CST - Business Wire Acadia Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026 Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, CA. Catherine Owen Adams, Chief Executive Officer will represent the company in a session scheduled on Tuesday, January 13, 2026, at 9:45 a.m. Pacific Time / 12:45 p.m. Eastern Time. A live webcast of Acadias presentation will be accessible on the companys website, acadia.com, under the investors section and an archi
20-Nov-2025 3:05 PM CST - Business Wire Acadia Pharmaceuticals to Participate in Citis 2025 Global Healthcare Conference Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate in a fireside chat at Citis 2025 Global Healthcare Conference on Tuesday, December 2, 2025 at 9:45 a.m. Eastern Time. A live webcast of Acadias fireside chat will be accessible on the companys website, acadia.com, under the investors section and an archived recording will be available on the website for approximately one month following the presentation. About Acadia Pharmaceutical
5-Nov-2025 3:05 PM CST - Business Wire Acadia Pharmaceuticals Reports Third Quarter 2025 Financial Results and Operating Overview Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced its financial results for the third quarter ended September 30, 2025. Acadia delivered another strong quarter, generating total revenue of $278.6 million, said Catherine Owen Adams, Chief Executive Officer. NUPLAZID achieved record sales of $177.5 million representing a significant inflection driven by an acceleration in new prescriptions. DAYBUE delivered $101.1 million in sales, driven by the expansion o
28-Oct-2025 3:05 PM CST - Business Wire Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate at two upcoming investor conferences: UBS Global Healthcare Conference Fireside Chat: Monday, November 10, 2025 at 2:00 p.m. Eastern Time in Palm Beach Gardens, FL Jefferies Global Healthcare Conference in London Presentation: Tuesday, November 18, 2025 at 8:30 a.m. Greenwich Mean Time in London Live webcasts of each will be accessible on the companys website, acadia.com, under the i
15-Oct-2025 3:05 PM CST - Business Wire Acadia Pharmaceuticals to Announce Third Quarter 2025 Financial Results on November 5, 2025 Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report third quarter 2025 financial results on Wednesday, November 5, 2025, after the close of the U.S. financial markets. Acadias management team will also host a conference call and webcast on November 5, 2025, at 4:30 p.m. Eastern Time. The conference call will be available on Acadias website, acadia.com under the investors section and will be archived there until February 5, 2026. The confe
26-Aug-2025 3:05 PM CST - Business Wire Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate at three upcoming investor conferences: Morgan Stanley 23rd Annual Global Healthcare Conference Fireside Chat: Monday, September 8, 2025 at 10:45 a.m. Eastern Time in New York, NY H.C. Wainwright 27th Annual Global Investment Conference Fireside Chat: Tuesday, September 9, 2025 at 8:00 a.m. Eastern Time in New York, NY TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Ep
6-Aug-2025 3:05 PM CST - Business Wire Acadia Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operating Overview Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced its financial results for the second quarter ended June 30, 2025. Acadia continued to build momentum in the second quarter, resulting in total revenue of $264.6 million, said Catherine Owen Adams, Chief Executive Officer. NUPLAZID delivered a very strong quarter, particularly in terms of referrals and new patient starts, driven by strong commercial execution and increased engagement from our direct-to-cons
5-Aug-2025 3:05 PM CST - Business Wire Acadia Pharmaceuticals to Participate in the Canaccord Genuity 45th Annual Growth Conference Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate in a fireside chat at Canaccord Genuity 45th Annual Growth Conference on Wednesday, August 13, 2025 at 2:30 p.m. Eastern Time. A live webcast of Acadias fireside chat will be accessible on the companys website, Acadia.com, under the investors section and an archived recording will be available on the website for approximately one month following the presentation. About Acadia Pharma
13-Jan-2026 8:00 AM CST - Business Wire Acadia Pharmaceuticals Provides Business and Pipeline Updates at 44th Annual J.P. Morgan Healthcare Conference Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced multiple business updates and progress on the Company's neurological and rare disease drug candidates, which will be discussed today during a presentation by Catherine Owen Adams, Chief Executive Officer, at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, CA. 2026 marks a pivotal year for Acadia as we advance our strategy built for sustained growth and pipeline advancement, said Catherin
18-Dec-2025 3:05 PM CST - Business Wire Acadia Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026 Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, CA. Catherine Owen Adams, Chief Executive Officer will represent the company in a session scheduled on Tuesday, January 13, 2026, at 9:45 a.m. Pacific Time / 12:45 p.m. Eastern Time. A live webcast of Acadias presentation will be accessible on the companys website, acadia.com, under the investors section and an archi
20-Nov-2025 3:05 PM CST - Business Wire Acadia Pharmaceuticals to Participate in Citis 2025 Global Healthcare Conference Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate in a fireside chat at Citis 2025 Global Healthcare Conference on Tuesday, December 2, 2025 at 9:45 a.m. Eastern Time. A live webcast of Acadias fireside chat will be accessible on the companys website, acadia.com, under the investors section and an archived recording will be available on the website for approximately one month following the presentation. About Acadia Pharmaceutical
5-Nov-2025 3:05 PM CST - Business Wire Acadia Pharmaceuticals Reports Third Quarter 2025 Financial Results and Operating Overview Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced its financial results for the third quarter ended September 30, 2025. Acadia delivered another strong quarter, generating total revenue of $278.6 million, said Catherine Owen Adams, Chief Executive Officer. NUPLAZID achieved record sales of $177.5 million representing a significant inflection driven by an acceleration in new prescriptions. DAYBUE delivered $101.1 million in sales, driven by the expansion o
28-Oct-2025 3:05 PM CST - Business Wire Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate at two upcoming investor conferences: UBS Global Healthcare Conference Fireside Chat: Monday, November 10, 2025 at 2:00 p.m. Eastern Time in Palm Beach Gardens, FL Jefferies Global Healthcare Conference in London Presentation: Tuesday, November 18, 2025 at 8:30 a.m. Greenwich Mean Time in London Live webcasts of each will be accessible on the companys website, acadia.com, under the i
15-Oct-2025 3:05 PM CST - Business Wire Acadia Pharmaceuticals to Announce Third Quarter 2025 Financial Results on November 5, 2025 Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report third quarter 2025 financial results on Wednesday, November 5, 2025, after the close of the U.S. financial markets. Acadias management team will also host a conference call and webcast on November 5, 2025, at 4:30 p.m. Eastern Time. The conference call will be available on Acadias website, acadia.com under the investors section and will be archived there until February 5, 2026. The confe
26-Aug-2025 3:05 PM CST - Business Wire Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate at three upcoming investor conferences: Morgan Stanley 23rd Annual Global Healthcare Conference Fireside Chat: Monday, September 8, 2025 at 10:45 a.m. Eastern Time in New York, NY H.C. Wainwright 27th Annual Global Investment Conference Fireside Chat: Tuesday, September 9, 2025 at 8:00 a.m. Eastern Time in New York, NY TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Ep
6-Aug-2025 3:05 PM CST - Business Wire Acadia Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operating Overview Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced its financial results for the second quarter ended June 30, 2025. Acadia continued to build momentum in the second quarter, resulting in total revenue of $264.6 million, said Catherine Owen Adams, Chief Executive Officer. NUPLAZID delivered a very strong quarter, particularly in terms of referrals and new patient starts, driven by strong commercial execution and increased engagement from our direct-to-cons
5-Aug-2025 3:05 PM CST - Business Wire Acadia Pharmaceuticals to Participate in the Canaccord Genuity 45th Annual Growth Conference Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate in a fireside chat at Canaccord Genuity 45th Annual Growth Conference on Wednesday, August 13, 2025 at 2:30 p.m. Eastern Time. A live webcast of Acadias fireside chat will be accessible on the companys website, Acadia.com, under the investors section and an archived recording will be available on the website for approximately one month following the presentation. About Acadia Pharma
